Stock AVCT AVACTA GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Delayed London S.E.
Other stock markets
 03:38:37 02/05/2024 pm IST 		5-day change 1st Jan Change
45.58 GBX -2.49% Intraday chart for Avacta Group Plc +2.44% -60.87%
01/05 Avacta picks Christina Coughlin to replace long-serving CEO AN
30/04 EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down AN

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
AVACTA GROUP PLC Stock Avacta Group Plc
-60.87% 207M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.17% 104B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.87% 97.47B
B+
ARGENX SE Stock argenx SE
+3.76% 22.25B
B
BIONTECH SE Stock BioNTech SE
-14.77% 21.68B
B+
GENMAB A/S Stock Genmab A/S
-9.05% 18.2B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.55% 14.39B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.75% 12.37B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AVCT Stock
  4. Ratings Avacta Group Plc